# Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

> **NCT00107289** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 200 (estimated)

## Conditions studied

- Neuroblastoma
- Pheochromocytoma

## Interventions

- **DRUG:** iobenguane I 131

## Key facts

- **NCT ID:** NCT00107289
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2006-05
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107289, "Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00107289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*